Filing Details
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNASDAQ:ENTA
ENANTA PHARMACEUTICALS INC (ENTA) Reports Material Event to SEC
Filing Details ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market Context…
Market Context
ENANTA PHARMACEUTICALS INC's stock currently trades at $15.11 with a market capitalization of $301.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ENANTA PHARMACEUTICALS INC's stock.
All SEC filings for ENANTA PHARMACEUTICALS INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ENTA Stock Page
Frequently Asked Questions
Where can I read ENTA's SEC filings?
Browse all filings on our ENTA SEC filings page.
What types of SEC filings does ENANTA PHARMACEUTICALS INC file?
Public companies like ENANTA PHARMACEUTICALS INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
